We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0A8M market cap is 0. The company's latest EPS is USD -4.5108 and P/E is -0.65.
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 7.32M | 27.63M | 65.63M | 96.67M | 107.4M |
| Operating Income | -16.85M | -21.13M | -58.87M | -111.56M | -12.33M |
| Net Income | -27.13M | -13.62M | -58.29M | -110.17M | -17.05M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 34.72M | 152.84M | 265.67M | 137.62M | 136.46M |
| Total Liabilities | 27.63M | 57.82M | 128.1M | 91.53M | 97.11M |
| Total Equity | 7.09M | 95.02M | 137.57M | 46.09M | 39.36M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -13.83M | -28.37M | -25.96M | -28.82M | -5.13M |
| Investing | -1.06M | -5.66M | -2.78M | -3.25M | -117k |
| Financing | 19.08M | 71.07M | 30.31M | 1.53M | 8.87M |
| Market Cap | 0 |
| Price to Earnings Ratio | -0.65 |
| Price to Sales Ratio | 0.1 |
| Price to Cash Ratio | 0.48 |
| Price to Book Ratio | 0.28 |
| Dividend Yield | - |
| Shares Outstanding | 3.78M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Aytu Biopharma Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.aytubio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
